Amgen Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company's total revenues were $5,011 million against $4,421 million a year ago. Operating income was $1,187 million against $1,088 million a year ago. Income before income taxes was $1,014 million against $923 million a year ago. Net income was $1,021 million or $1.33 diluted per share against $788 million or $1.01 diluted per share a year ago. Adjusted income before income taxes was $1,594 million against $1,297 million a year ago. Adjusted net income was $1,391 million or $1.82 diluted per share against $1,088 million or $1.40 diluted per share a year ago. Cash flows from operations were $1,835 million against $812 million a year ago. Capital expenditures were $201 million against $200 million a year ago.

For the full year, the company's total revenues were $18,676 million against $17,265 million a year ago. Operating income was $5,867 million against $5,577 million a year ago. Income before income taxes was $5,265 million against $5,009 million a year ago. Net income was $5,081 million or $6.33 diluted per share against $4,345 million or $5.52 diluted per share a year ago. Adjusted income before income taxes was $6,404 million against $6,089 million a year ago. Adjusted net income was $5,814 million or $7.60 diluted per share against $5,119 million or $6.51 diluted per share a year ago. Cash flows from operations were $6,291 million against $5,882 million a year ago. Capital expenditures were $693 million against $689 million a year ago.

For the full year 2014, the Company expects total revenues to be in the range of $19.2 billion to $19.6 billion and adjusted EPS to be in the range of $7.90 to $8.20. GAAP diluted EPS to be in the range of $6.89 to $7.19. This includes an $800 million incremental operating income contribution due to the end of the ENBREL profit share. Adjusted tax rate to be in the range of 15% to 16%. This assumes the federal R&D credit will be extended for 2014 and also includes the impact of the foreign tax credit associated with the Puerto Rico excise tax. The Puerto Rico excise tax credit reduces the adjusted rate by three to four percentage points. Capital expenditures to be approximately $800 million. GAAP tax rate to be in the range of 11% -12%.